Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 2,645,600 | 2,690,600 | 2,517,700 | 2,483,500 | 2,493,200 |
| Cost of Goods | 371,900 | 342,600 | 368,000 | 318,700 | 308,600 |
| Gross Profit | 2,273,700 | 2,348,000 | 2,149,700 | 2,164,800 | 2,184,600 |
| Operating Expenses | 5,789,300 | 1,209,100 | 1,162,200 | 1,127,400 | 1,158,800 |
| Operating Income | -3,514,700 | 1,139,500 | 988,500 | 1,038,100 | 1,026,400 |
| Interest Expense | 9,900 | 10,400 | 10,600 | 10,900 | 11,200 |
| Other Income | 133,400 | 150,000 | 169,700 | 152,000 | 146,300 |
| Pre-tax Income | -3,391,200 | 1,279,100 | 1,147,600 | 1,179,200 | 1,161,500 |
| Income Tax | 202,400 | 179,500 | 178,800 | 143,900 | 245,800 |
| Net Income Continuous | -3,593,600 | 1,099,600 | 968,800 | 1,035,300 | 915,700 |
| Net Income | $-3,593,600 | $1,099,600 | $968,800 | $1,035,300 | $915,700 |
| EPS Basic Total Ops | -13.92 | 4.26 | 3.77 | 4.01 | 3.55 |
| EPS Basic Continuous Ops | -13.92 | 4.26 | 3.76 | 4.01 | 3.55 |
| EPS Diluted Total Ops | -13.92 | 4.21 | 3.71 | 3.97 | 3.52 |
| EPS Diluted Continuous Ops | -13.92 | 4.21 | 3.72 | 3.97 | 3.52 |
| EPS Diluted Before Non-Recurring Items | -13.27 | 4.29 | 3.57 | 3.67 | 3.53 |
| EBITDA(a) | $-3,460,700 | $1,193,000 | $1,047,500 | $1,080,200 | $1,067,800 |